Oncology Podcast

Podcast: Treatment Intensification in mCSPC – The Nurse Perspective

Listen as GU oncology nurses share their views in this clinical update podcast

Brenda Martone

Jennifer Sutton

Publication Date

Jun 2023

I agree that this programme:

Was valuable to me

1/3

Has improved my knowledge of this topic:

2/3

Is likely to change my clinical practice:

3/3

Listen and follow our podcasts on:

Bayer

Listen on Spotify Podcasts

Listen on Apple Podcasts

In this podcast, oncology nurses Brenda Martone and Jennifer Sutton discuss how to use data to select the most appropriate treatments for patients with metastatic castration-sensitive prostate cancer. They also share the importance of being able to explain these clinical decisions to patients and reassure them that earlier intensive treatment can prolong overall survival without seriously impacting quality of life.

Clinical Takeaways

Treatment intensification with triplet therapy (ADT plus NHA plus docetaxel) should be the new standard of care for high-risk, high-volume, mCSPC patients who are fit for chemotherapy
Early treatment intensification should be considered for these patients whilst they are still well enough to tolerate intensive treatment
When determining which triplet regimen would be the most appropriate for your patient, it is important to consider the patient's co-morbidities, risk profile and potential drug-drug interactions
The nurse has a key role in communicating the benefits and risks of different triplet regimens to the patients
Patient education on potential side effects and early reporting of them is essential to optimise patient outcomes

This educational podcast is endorsed by

Brenda Martone is a board-certified adult nurse practitioner working in GU oncology at Northwestern Medicine, Chicago, IL. She graduated with her BSN from Concordia College/West Suburban College of Nursing in 1989, received her MSN/CNS degree from Loyola University in 1996 and then completed a post-master’s certificate to become an adult nurse practitioner from Rush University in 2008. Brenda is an advanced oncology certified nurse practitioner and has been an oncology nurse for over 31 years. She has been a member of several medical advisory boards, as well as developed programs about metastatic and non-metastatic castration-resistant prostate cancer. Brenda Martone is a frequent national and regional lecturer and a member of the Advanced Practitioner Society for Hematology and Oncology (APSHO).

Brenda Martone has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Astellas, Bhealth and Pfizer.

Jennifer Sutton is a registered nurse and the Director of Nursing and Administration at Carolina Urologic Research Center in Myrtle Beach, SC. After receiving her Bachelor of Science degree in Exercise Science with a minor in Chemistry from the University of South Carolina, she earned her Associate Degree in Nursing from Horry Georgetown Technical College. Jennifer is a member of the Society of Urologic Nurses and Associates, the Oncology Nursing Society, and the Association of Clinical Research Professionals (ACRP). She is an ACRP-certified Clinical Research Coordinator and has more than 11 years of experience managing and administering cutting edge therapies to patients with genitourinary malignancies and other urologic disorders. Additionally, she manages a team of research professionals that coordinate phase I-IV clinical trials in all areas of urology. In recent years, she has served on multiple prostate cancer and bladder cancer advisory boards and has published articles on emerging prostate cancer treatments and effective structuring and management of a clinical research center.

Jennifer Sutton has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Bayer, Janssen, Merck, Myovant and SeSen Bio.